Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 1:15:674-676.
doi: 10.18632/oncotarget.28652.

Transplant or no transplant for TP53 mutated AML

Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R Litzow, Mohamed A Kharfan-Dabaja
Editorial

Transplant or no transplant for TP53 mutated AML

Talha Badar et al. Oncotarget. .
No abstract available

Keywords: AML; TP53 mutation; allogeneic stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Transplant outcome with complex CG.
Kaplan Meier survival curves demonstrating (A) Event-free survival and (B) Overall survival among TP53-mutated AML patients with and without complex cytogenetics.
Figure 2
Figure 2. Diagrammatic illustration of factor that predicted transplant outcomes in TP53-mutated AML (Badar et al., Leukemia 2023).
See this image and copyright information in PMC

References

    1. Papaemmanuil E, et al.. N Engl J Med. 2016; 374:2209–21. 10.1056/NEJMoa1516192. - DOI - PMC - PubMed
    1. Badar T, et al.. Haematologica. 2024. 10.3324/haematol.2024.285000. - DOI - PMC - PubMed
    1. Daver NG, et al.. Cancer Discov. 2022; 12:2516–29. 10.1158/2159-8290.CD-22-0332. - DOI - PMC - PubMed
    1. Badar T, et al.. Blood Cancer J. 2024; 14:32. 10.1038/s41408-024-01000-2. - DOI - PMC - PubMed
    1. Badar T, et al.. Leukemia. 2023; 37:799–806. 10.1038/s41375-023-01847-7. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources